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Hyperfunction of the mTORC1 pathway has been
associated with idiopathic and syndromic forms of
autism spectrum disorder (ASD), including tuberous
sclerosis, caused by loss of either TSC1 or TSC2. It
remains largely unknown how developmental pro-
cesses and biochemical signaling affected by
mTORC1 dysregulation contribute to human
neuronal dysfunction. Here, we have characterized
multiple stages of neurogenesis and synapse forma-
tion in human neurons derived from TSC2-deleted
pluripotent stem cells. Homozygous TSC2 deletion
causes severe developmental abnormalities that
recapitulate pathological hallmarks of cortical mal-
formations in patients. Both TSC2+/ and TSC2/
neurons display altered synaptic transmission
paralleled bymolecular changes in pathways associ-
ated with autism, suggesting the convergence of
pathological mechanisms in ASD. Pharmacological
inhibition ofmTORC1 corrects developmental abnor-
malities and synaptic dysfunction during indepen-
dent developmental stages. Our results uncouple
stage-specific roles of mTORC1 in human neuronal
development and contribute to a better understand-
ing of the onset of neuronal pathophysiology in tu-
berous sclerosis.86 Cell Reports 15, 86–95, April 5, 2016 ª2016 The Authors
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Increased activity of the mammalian target of rapamycin com-
plex 1 (mTORC1) pathway has been implicated in autism spec-
trum disorder (ASD) and related neurodevelopmental disorders.
Indeed, several monogenic disorders associated with a high rate
of autism are caused by mutations in negative regulators of the
pathway (Bourgeron, 2009), and mTORC1 overactivation has
been detected in temporal lobe of patients with idiopathic ASD
(Tang et al., 2014). Moreover, alterations in processes down-
stream of mTORC1 recapitulate ASD-like behavioral abnormal-
ities and cellular pathology in mice (Santini et al., 2013; Gkogkas
et al., 2013; Tang et al., 2014). Thus, a better understanding of
the molecular and cellular consequences of mTORC1 hyper-
function might help to identify novel targets for therapeutic
intervention.
Tuberous sclerosis (TSC) is a severe multisystem disorder that
presents with complex neuropsychiatric symptoms including
autism, intellectual disability, and epilepsy (Crino et al., 2006;
Rosser et al., 2006). Neuroanatomical abnormalities include for-
mation of cortical tubers, which are disorganized regions of the
cortex characterized by the presence of dysplastic neurons
with immature electrophysiological properties (Cepeda et al.,
2012). The disease is caused by heterozygous loss-of-function
mutations in the genes coding for TSC1 or TSC2. Loss of hetero-
zygosity due to somatic mutations of the functional allele has
been detected in hamartomas, while its role in tuber formation
remains controversial (Henske et al., 1997; Chan et al., 2004;
Crino et al., 2010; Qin et al., 2010). TSC1 and TSC2 form acreativecommons.org/licenses/by-nc-nd/4.0/).
heterodimeric complex that functions as a negative regulator of
mTORC1 through the inhibition of Rheb, a Ras family GTPase
(Inoki et al., 2003; Tee et al., 2003). Increased mTORC1 kinase
activity likely underlies TSC pathophysiology and is a patholog-
ical hallmark of brain malformations in patients (Talos et al.,
2008).
Deletion of TSC1/2 in animal models affects a wide range of
neuronal processes, and inhibition of mTORC1 corrects specific
cellular, neuroanatomical, and neurological phenotypes (Meikle
et al., 2007, 2008; Magri et al., 2011; Bateup et al., 2013; Tava-
zoie et al., 2005). The direct cellular and synaptic consequences
of TSC2 deletion in human neurons are unknown. Specifically, it
is still unclear how increased TSC-mTORC1 pathway activity
precipitates the onset of human neuronal dysfunction, how it
altersmultiple neurodevelopmental stages, and if andwhen phe-
notypes can be reversed.
Here, we used genome-engineered TSC2+/ and TSC2/ hu-
man pluripotent stem cells to recapitulate the heterozygous loss
of function underlying the disorder and study the effect of com-
plete loss of TSC2 in neuronal development, respectively.
Combining a neuronal differentiation protocol and molecular,
cellular, and electrophysiological analyses, our results reveal
the effects of alterations of the TSC2-mTORC1 pathway on hu-
man neurodevelopment and synaptic physiology.
RESULTS
Generation of an Allelic Series of TSC2 Deleted Human
Embryonic Stem Cell Lines
Zinc-finger nuclease-mediated targeted gene disruption was
used to generate heterozygous and homozygous deletions of
TSC2 in the well-characterized SA001 human embryonic stem
cell (hESC) line (Englund et al., 2010), which we have previously
used to study neuronal maturation (Dunkley et al., 2015). We
generated an isogenic allelic series of TSC2 deletions by insert-
ing a neomycin selection cassette into one (TSC2+/) or both
(TSC2/) alleles or into the AAVS1 safe harbor locus (TSC2+/+)
(Figure 1A). Correct gene targeting was established by genomic
PCR amplification across the disruption cassette (Figures S1A
and S1B), and absence of additional genomic integrations was
confirmed by targeted locus amplification (de Vree et al., 2014)
(Figure S1C). Gene targeting resulted in decreased TSC2 protein
levels in heterozygous lines and absence of the protein in homo-
zygous clones (Figure 1B). To determine whether TSC2mutation
affected mTORC1 function in hESCs, we monitored phosphory-
lation levels of the downstream substrate 40S ribosomal protein
S6 (RPS6) and found increased phosphorylation in TSC2/, but
not TSC2+/, lines (Figure S1D). We observed no differences in
hESC colony morphology (Figures 1C and S1E), proliferation,
pluripotency, or spontaneous differentiation capacity (data not
shown). These results suggest that TSC2 deletion and mTORC1
hyperfunction do not grossly affect pluripotency of hESCs.
Deletion of TSC2 Causes Abnormal Structural
Organization of Neuroectodermal Rosettes
In vivo, Tsc2 ablation leads to embryonic lethality and defective
neural tube closure in mouse embryos at E11.5 (Kobayashi et al.,
1999). We therefore asked whether deletion of TSC2 alters hu-man neuroectodermal rosette formation, the in vitro correlate
of in vivo cortical neuroepithelium development (Shi et al.,
2012). We induced neuroectodermal differentiation using a
modified dual-SMAD inhibition protocol (Figure S2A; Experi-
mental Procedures). Neuroepithelial progenitors expressed the
forebrain rosette neural progenitor markers PLZF, Nestin,
Pax6, and SOX1, suggesting efficient differentiation in control
and mutant lines (Figures 1E and S2C; data not shown). The
typical apicobasal polarity was mostly maintained in rosettes
from all genotypes, as the tight junction protein zonula occludens
1 (ZO1) and M phase nuclei were oriented toward the lumen of
the rosettes (Figures 1E and S2C) (Falk et al., 2012; Go¨tz and
Huttner, 2005). However, TSC2/ rosettesweremore heteroge-
neous in size due to formation of enlarged rosettes (Figures 1E,
1F, and S2D). Cell size was comparable across genotypes at
this stage, suggesting that enlarged rosette size was likely due
to increased cell number (Figure S2E). Importantly, this cellular
phenotype correlated with overactivation of the mTORC1
pathway in TSC2/ lines (Figure 1D). We conclude that biallelic
TSC2 deletion causes mTORC1 hyperfunction in neuroectoder-
mal rosettes, which in turn impairs their structural organization.
Deletion of TSC2 Alters Neuronal Proliferation,
Differentiation, and Morphology in a Gene-Dosage-
Dependent Manner
During early neuroectodermal specification, no alterations were
observed in TSC2+/ lines. To investigate whether heterozygous
TSC2 loss of function, mimicking the TSC patient genotype,
leads to neural dysfunction during later stages of development,
we generated neural stem cells (NSCs) that can be differentiated
into functional neurons (Figures S2A and S2F–S2J; see Experi-
mental Procedures for details). To model a physiologically rele-
vant neuronal network with excitatory and inhibitory neuronal
connectivity, we utilized a protocol that differentiates NSCs to
glutamatergic and GABAergic neurons (HuC/D+ cells, 50.9% ±
3.2%;GABA+/HuC/D+ cells, 11.3% ± 5.8%at day 28 of differen-
tiation; Figures 2A, S2A, and S2B) (Dunkley et al., 2015).
TSC2 mutant lines showed early neuronal alterations. At day
14 of differentiation, TSC2/ showed a 55% reduction in the
number of postmitotic (HuC/D+) neurons. The phenotype was
less pronounced (26% reduction) and transient in TSC2+/
lines (Figures 2B, 2C, and S3G). TSC2/ cells exhibited reduced
expression of neuronal progenitor markers and aberrant prolifer-
ation already 7 days of differentiation (Figures S3A–S3C). We
investigated the potential mechanisms underlying the decreased
neuronal content in TSC2/ lines and found a small but signifi-
cant increase in cell death of TSC2/ neurons at day 7 of differ-
entiation (Figure S3E). In addition, TSC2/ lines showed an
increased differentiation toward the astroglial lineage, as shown
by upregulation of the astroglia marker NFIA and increase in
GFAP+ cells at late stages of differentiation (Figures S3D, S2L,
and S2M). To understand the molecular correlates of the
observed alterations in neuronal differentiation, we studied the
expression of several genes and proteins relevant to neuronal
development (Tables S1 and S2). TSC2+/ and TSC2/ imma-
ture neurons showed increased expression of neural stem cell
and proliferation markers (SOX2, NESTIN, and PCNA) and a
concomitant downregulation of genes associated with neuronalCell Reports 15, 86–95, April 5, 2016 87
Figure 1. TSC2 Deletion Leads to mTORC1 Hyperfunction and Altered Structural Organization of Neuroectodermal Rosettes
(A) Gene targeting strategy using zinc-finger nucleases. For control lines (TSC2+/+), a neomycin resistance cassette was inserted into intron 1 of one allele of the
AAVS1 (PPP1R12C) locus. For TSC2+/ and TSC2/ lines the selection cassette was inserted in exon 11 of one or both alleles of TSC2, respectively.
(B and D) Proteins from hESCs (25 mg; B) and 3-day-old neural rosettes (12.5 mg; D) were analyzed by SDS-PAGE/immunoblotting.
(C) Representative bright-field images of hESC clonal isolates. Scale bar, 100 mm.
(E) Confocal images of 2.5-day-old neural rosettes. Confocal z-axis stacks were acquired and reconstructed. Scale bars, 100 mm.
(F) Size of 2.5-day-old rosettes. Data represent median ± SEM of three independent derivations, p < 0.05 TSC2/ versus TSC2+/+ and TSC2+/.
(B, D, and F) A and B indicate two clones with the same genotype. See also Figures S1 and S2.maturation and synapse formation. Intriguingly, we observed
dysregulation of the chloride transporters NKCC1 (SLC12A2)
and KCC2 (SLC12A5), which affect neuronal excitability in
response to GABA, are dynamically regulated during brain
development and are altered in cortical tubers from TSC patients
(Figures 2E and S3F) (Ben-Ari et al., 2012; Jagasia et al., 2009;
Talos et al., 2012). At day 14 of differentiation, TSC2/ (but
not TSC2+/) neurons showed increased soma size, recapitu-
lating what is observed in cortical tubers and attributed to
mTORC1 hyperfunction (Figure 2B, right; and Figure 2D) (Ruppe
et al., 2014). To assess morphological alterations in mature neu-
rons (Figures S2K and S2N), we analyzed biocytin-filled 6- to
8-week-old neurons (Figure 2F). TSC2/ neurons exhibited
increased dendritic arborization measured by Sholl analysis,
increased soma size, and an 2-fold increase in total dendritic
length (Figures 2G, S3H, and S3I). TSC2+/ neurons did not
show gross morphological changes. In a correlation analysis,88 Cell Reports 15, 86–95, April 5, 2016we observed a positive correlation of moderated t statistics
values for transcripts and proteins between TSC2+/ and
TSC2/ lines compared to controls at days 14 and 41 of differ-
entiation (r = 0.617 and r = 0.298 for transcripts and r = 0.552 and
r = 0.444 for proteins at days 14 and 41, respectively; Figure 2H).
Cluster analysis revealed a trend toward downregulation of
genes relevant for synaptic transmission in both TSC2+/ and
TSC2/ neurons. The cluster of proteins/transcripts with the
largest effect included genes and pathways associated with
autism including CNTNAP2, NLG3, and KCC2 (Figure 2I). In
addition, we observed in both genotypes downregulation of
RBFOX1, a splicing factor reduced in brains from idiopathic
ASD patients (Figure S3J) (Fogel et al., 2012, Voineagu et al.,
2011). In the aggregate, these data indicate that monoallelic
deletion of TSC2 causes persistent dysregulation of ASD-rele-
vant genes that is similar to that observed in TSC2/ cells but
whose extent remains below the threshold required to elicit
Figure 2. TSC2 Deletion Causes Deficits in Neuronal Proliferation, Differentiation, and Maturation
(A) Neuronal differentiation protocol outline. NSCs, neural stem cells; R, replating. For details, see Experimental Procedures.
(B) Representative confocal images of day 14 differentiated neurons. Confocal z-axis stacks were acquired and reconstructed. Scale bars represent 100 mm (left)
and 10 mm (right).
(C and D) Neuronal content (C) and soma size (HuC/D+ area; D) in day 14 differentiated cultures. Experiments were as in (B); n = 4, *p < 0.05. Acquisition and
automated quantification performed with Operetta HCS. Data represent mean ± SEM. A and B indicate two clones with the same genotypes.
(E) qPCR quantitation of gene expression levels in day 14 differentiated cultures. Data are normalized to a pool of housekeeping genes and expressed as fold
change (log2) relative to TSC2
+/+ lines. Data represent mean ± 95% confidence interval, nR 4. All fold changes are statistically significant.
(F) Representative fluorescence images of biocytin-filled day 41–63 differentiated neurons. Confocal images were acquired with Zen software. Scale bar, 50 mm.
(G) Sholl analysis of experiments as in (F). TSC2+/+: n = 6, TSC2+/: n = 4, TSC2/: n = 8. Data represent mean ± SEM.
(legend continued on next page)
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Figure 3. Neuronal Maturation Reveals mTORC1 Hyperfunction in TSC2+/ Neurons
(A and B) Proteins (10 mg) from NSCs (A) and day 35 differentiated neurons (B) were analyzed by SDS-PAGE/immunoblotting. Where indicated, cells were treated
as follows: FEB (+ growth factors day 0) or BGAA (+ growth factors day 35) medium overnight; R, 50 nM rapamycin for 1.5 hr; starvation in Neurobasal medium
( growth factors) for 5 hr; IGF1 (10 ng/ml) (I) or BDNF (20 ng/ml) (B) for 30 min. DMSO was vehicle control in untreated cells. See also Figure S4.most of the early cellular phenotypes seen in the full knockout. In
addition, our molecular analysis suggests that TSC2 deletion
leads to alterations in synapse biology in both genotypes.
TSC2 Heterozygous Deletion Leads to mTORC1
Hyperfunction in Differentiating Neuronal Cultures
To address whether the observed molecular and cellular deficits
correlated with alterations in mTOR signaling, we monitored the
phosphorylation status of mTORC1 downstream substrates in
response to physiologically relevant modulators (insulin-like
growth factor [IGF] and brain-derived neurotrophic factor
[BDNF]) and known inhibitors (rapamycin and nutrient starvation)
of the pathway. As expected, TSC2 protein was reduced to
50% in TSC2+/ lines and absent in TSC2/ lines (Figures
S4A and S4B). Lines from all genotypes exhibited an IGF1-
dependent increase in phosphorylation of the mTORC2 sub-
strate AKT at serine 473 (Sarbassov et al., 2005) in both NSCs
(Figures 3A and S4E) and neurons (Figures 3B and S4F). In
contrast, BDNF elicited a response only in neurons, consistent
with functional maturation of the culture (Figures 3A, 3B, S4C,
and S4D). Phosphorylation of mTORC1 targets S6 and eukary-
otic translation initiation factor 4E binding protein 1 (4EBP1)
showed TSC2 gene-dosage-dependent alterations. TSC2/
cells showed constitutive activation of mTORC1 as shown by
increased phosphorylation of S6 and 4EBP1 even upon with-
drawal of growth factors, a condition which silences the pathway
in control lines. Furthermore, TSC2/ lines exhibited a marked
reduction of AKT phosphorylation, previously ascribed to
mTORC1-dependent negative feedback signaling (Shah and(H) Correlation analysis between TSC2+/ and TSC2/ lines of t statistics values c
14 and day 41 of differentiation. Pearson correlation values are indicated. Red lin
(I) Cluster analysis (using Euclidean distance and Ward clustering) based on the t s
genotypes at day 41. Analysis on genes for which both protein (P) and transcript
marked and consistent effects.
See also Figures S2 and S3 and Tables S1 and S2.
90 Cell Reports 15, 86–95, April 5, 2016Hunter, 2006, Harrington et al., 2004). Indeed, the reduction
was partially reverted upon rapamycin treatment (from 34%
to 84% of TSC2+/+ at day 0 and from 12% to 42% of
TSC2+/+ at day 35, in the presence of growth factors without
and with rapamycin, respectively; Figures 3A, 3B, and S4H).
Surprisingly, although we could not observe gross differential
regulation between control and TSC2+/ lines at the NSC stage
(Figure 3A), phosphorylation of S6 and 4EBP1 was increased
in TSC2+/ lines at day 35 (Figures 3B and S4D; quantification
in Figure S4H).
Interestingly, upon differentiation, negative regulators of the
mTOR pathway were upregulated in control lines (TSC1 and
TSC2, 3-fold; PTEN, 10-fold), suggesting a tight regulation
of the pathway in neurons (Figures S4A and S4B). In mature neu-
rons, TSC1 protein expression was reduced in TSC2+/ and
TSC2/ lines (Figures S4A and S4B). This suggests that the
mTORC1 pathway is tightly regulated during neuronal matura-
tion and that an 50% reduction in TSC2 leads to a molecular
phenotype in neurons. Moreover, homozygous deletion of
TSC2 leads to constitutive activation of mTORC1 and dysregula-
tion of feedback signaling pathways as observed in cortical
tubers (Ruppe et al., 2014).
mTORC1 Inhibition Corrects Excitability and
Synaptogenesis Deficits Independently of Early
Neurodevelopmental Alterations
We next asked if, and at what stage during neuronal differentia-
tion, cellular and electrophysiological phenotypes could be
corrected by inhibition of mTORC1. Rapamycin treatment ofompared to TSC2+/+ lines calculated for 254 transcripts and 196 proteins at day
e is calculated using LOWESS smooth splines.
tatistics representing significance of change relative to wild-type (WT) for both
(T) measurements were available. A sub-cluster around EPHB1 showed very
(legend on next page)
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TSC2/ NSCs during the first 7 days of differentiation reverted
cell density and soma size to control levels but failed to correct
the deficit in neuronal differentiation (Figures 4A and 4B). The
latter phenotype was partially ameliorated when the treatment
was applied on proliferating NSCs during the patterning stage,
suggesting that earlier application of rapamycin during neuroec-
todermal differentiation might be beneficial (Figure S4I).
In mature neurons, whole-cell patch-clamp recordings re-
vealed that TSC2/ neurons had an 50% reduction in electri-
cal input resistance and an 2-fold increase in membrane
capacitance (Figures 4C and S4J), which correlated with
increased total dendritic length of individual cells (Figure S4K).
Normalizing the input conductance by the capacitance in individ-
ual cells revealed no significant differences between genotypes,
indicating that the conductance density of open ion channels at
the resting membrane potential was not significantly different
(data not shown) and suggesting that the alterations in passive
membrane properties are likely due to increased cell size. Since
the increased capacitance and decreased input resistance
might impact electrical excitability, wemeasured action potential
(AP) firing in response to 1-s current pulses with increasing cur-
rent amplitudes. While TSC2+/ neurons responded similarly to
control cells, TSC2/ neurons required a 2-fold-larger current
amplitude to generate the same frequency of AP firing (Figures
4D and 4E). Similar results were obtained when measuring the
AP firing probability in response to brief 10-ms current pulses
with increasing amplitude (Figures S4L and S4M). The functional
properties of voltage-gated sodium and potassium channels
were unlikely to be different, since the shapes of individual APs
were indistinguishable across genotypes (Figures S4N–S4P).
To test whether changes in electrical excitability were due to
enhanced mTORC1 activity, we treated cells for 7 weeks with
2 nM rapamycin, a concentration that inhibits mTORC1 signaling
(Figure S4G), starting at day 7, after early neuronal differentiation
had occurred. Remarkably, after treatment, both passive mem-
brane properties and AP firing were indistinguishable from con-
trol (Figures 4C–4E, S4J, and S4L).Figure 4. Reversal of Neurodevelopmental and Synaptogenesis Defici
(A) Outline of phenotypic reversal experiments with rapamycin treatment. NSCs,
(B) Cell density (DAPI+ nuclei/field), neuronal soma size (HuC/D+ area), and neur
Untreated: ten wells/plate, 27 fields/well, four plates; treated: three wells, 27 field
(C) Input resistance of day 56–63 differentiated neurons untreated or treatedwith 2
n = 4; TSC2/: untreated n = 31, treated n = 27.
(D) Representative recordings of action potentials (AP) induced by somatic curre
(E) AP firing frequency-current relationship calculated from recordings of action p
was constructed using Boltzmann sigmoidal fit in GraphPad Prism.
(F) Frequency of spontaneous EPSCs (5-min recording in the presence of 4 mMga
rapamycin n = 12, treated with 2 nM rapamycin for 3–4 weeks n = 7 or for 7 week
n = 10.
(G) Representative traces of sEPSCs quantified in (F).
(H) Frequency of mEPSC in day 56 - 63 differentiated neurons untreated or treate
treated n = 5; TSC2/: untreated n = 11, treated n = 12.
(I) Representative traces of mEPSCs quantified in (H) recorded in the presence o
(J) Representative traces of mEPSCs. Black line represents the average of 25 sin
(K) Amplitudes of mEPSCs in neurons untreated or treated with 2 nM rapamycin f
untreated n = 5, treated n = 6.
(L) Decay time constants of mEPSCs in neurons untreated or treated with 2 nM ra
TSC2/: untreated n = 5, treated n = 6.
Bar graphs represent mean ± SEM (C, E, F, H, K, and L); *p < 0.05; **p < 0.01. S
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synaptic function in TSC2+/ and TSC2/ neurons (Figure 2I).
To analyze glutamatergic synapse formation and excitatory syn-
aptic transmission, we recorded spontaneous excitatory synap-
tic currents (sEPSCs) and miniature excitatory synaptic currents
(mEPSCs) in the presence of the GABAA-receptor antagonist ga-
bazine (4 mM). The frequency of sEPSCs (0.57 ± 0.15Hz, n = 12,
control) was significantly reduced in TSC2+/ as well as in
TSC2/ neurons relative to control lines in a gene-dosage-
dependent manner (0.28 ± 0.05 Hz, p < 0.05, n = 24 and
0.16 ± 0.04 Hz, p < 0.01, n = 11, respectively; Figures 4F and
4G). The phenotype was reverted by long-term (7 weeks starting
at day 7 of differentiation), but not acute (2 hr starting at 8 weeks
of differentiation), treatment with rapamycin. To understand
whether the phenotype could be rescued at late developmental
stage by longer treatment, we applied rapamycin for 3–4 weeks
starting at 6 weeks of differentiation. The treatment fully cor-
rected the deficit in sEPSCs frequency (TSC2+/ with 3- to
4-week rapamycin: 0.69 ± 0.22 Hz, n = 7). To test whether the
reduction in frequency of sEPSCs was caused by decreased
excitability or a reduced number of synaptic connections, we re-
corded mEPCs in the presence of 0.5 mM TTX. Similarly to
spontaneous synaptic currents, mEPSC frequency (0.15 ±
0.04 Hz, n = 24) was reduced in mutant neurons (TSC2+/:
0.04 ± 0.02 Hz, n = 7; TSC2/: 0.01 ± 0.01, n = 11), indicating
a reduced number of glutamatergic synapses, and the pheno-
type was corrected by chronic rapamycin treatment (Figures
4H and 4I). Furthermore, rapamycin could correct the slight but
significant increase in the amplitude and decay time course of
average mEPSCs in TSC2/ neurons (Figures 4J–4L).
Taken together, these data show that neuronal and synaptic
alterations, including a deficit in glutamatergic synaptic trans-
mission, are triggered in a TSC2-gene-dosage-dependent
manner and can be corrected by pharmacological mTORC1 in-
hibition. Importantly, synaptic defects are corrected even when
rapamycin treatment is started after the establishment of synap-
tic network connectivity.ts by mTORC1 Inhibition
neural stem cells.
onal content (% of HuC/D+ cells / DAPI+ nuclei). Data represent mean ± SEM.
s/well. ***p < 0.001, ****p < 0.0001.
nM rapamycin for 7 weeks. TSC2+/+: n = 37, TSC2+/: untreated n = 39, treated
nt injections of 18 and 28 pA.
otentials induced by a 1-s pulse of somatic current injections DI = 2 pA. Curve
bazine). TSC2+/+: n = 12; TSC2+/: untreated n = 24, treated for 2 hr with 20 nM
s n = 12; TSC2/: untreated n = 11, treated with 2 nM rapamycin for 7 weeks
d with 2 nM rapamycin for 7 weeks. TSC2+/+: n = 24; TSC2+/: untreated n = 7,
f 0.5 mM TTX and 4 mM gabazine.
gle events. Gray line represents the biexponential fit of the average trace.
or 7 weeks. TSC2+/+: n = 18; TSC2+/: untreated n = 5, treated n = 4; TSC2/:
pamycin for 7 weeks. TSC2+/+: n = 18; TSC2+/: untreated n = 5, treated n = 4;
ee also Figure S4.
DISCUSSION
The pathophysiological mechanisms underlying neuroanatom-
ical and neurological alterations in patients affected by TSC
are largely unknown. Here, we show that TSC2 deletion leads
to exaggerated mTORC1 signaling during differentiation of hu-
man neurons in a gene-dosage-dependent manner, and this
correlates with molecular and cellular alterations at multiple
developmental stages. We show that TSC2 deletion alters
the structure of human neuroectodermal rosettes, providing
an in vitro correlate of neural tube formation deficits observed
during in vivo embryonic development. Interestingly, abnormal
rosette organization has been recently reported in hiPSCs car-
rying 15q11.2 microdeletion, a risk factor for schizophrenia
and autism, supporting a role for early neurodevelopmental
defects in neuropsychiatric disorders (Yoon et al., 2014). At
later stages, we show that heterozygous loss of TSC2 results
in a transient delay in early neuronal differentiation. Deficits
in neuronal differentiation have been suggested to lead to
abnormal brain wiring and could contribute to the altered con-
nectivity observed in TSC patients (Krishnan et al., 2010; La
Fata et al., 2014; Baumer et al., 2015). Furthermore, we
demonstrate that heterozygous and homozygous loss of
TSC2 leads to altered synaptogenesis and transmission. By in-
hibiting mTORC1 at different developmental stages, we show
that early neurodevelopment and synaptogenesis can be un-
coupled and corrected independently of each other. Indeed,
excitatory synapse reduction can be corrected in both geno-
types by long-term mTORC1 inhibition even after the onset
of early differentiation deficits. Importantly, the correction is
achieved even when the treatment is started at late differenti-
ation stages, after synaptic network connectivity has been
established.
Cortical tubers are a common neuropathological feature in
TSC patients and their role in epilepsy and cognitive impair-
ment is under close scrutiny (Jansen et al., 2007, 2008; Doherty
et al., 2005; Major et al., 2009). We show that homozygous
deletion of TSC2 recapitulates molecular, cellular, and electro-
physiological features observed in dysplastic neurons from
cortical tubers. Notably, alterations are dependent on
mTORC1-hyperactivity, as they can be corrected by rapamycin
treatment. Extending the functional characterization of our
TSC2 mutant neurons will contribute to understand the role of
altered mTORC1 signaling, excitability, and synaptic connectiv-
ity in the onset of neuronal network dysfunction and of epi-
lepsy, a pathological feature associated with TSC and involved
in the development of ASD.
Patients affected by TSC present with autism (50%) and co-
morbid symptoms including epilepsy (80%–90%) and varying
degrees of intellectual disability (45%) (Jeste et al., 2008; Crino
et al., 2006; Curatolo and Bombardieri, 2008). ASD is character-
ized by a remarkable heterogeneity in genetic causes and clinical
manifestations. Consequently, identifying convergence in ASD
biology remains an elusive challenge. Using TSC as a model of
monogenic forms of ASD, we have characterized phenotypes
in human neurons including deficits in synaptogenesis and alter-
ations in pathways and genes previously associated with ASD.
Extending this analysis to multiple genetically defined modelsof ASD will provide an unprecedented opportunity to link human
genetics to neuronal phenotypes and potentially identify shared
pathophysiological mechanisms.
EXPERIMENTAL PROCEDURES
Genome Editing
Plasmids encoding zinc-finger nucleases (ZFNs) targeting exon 11 of TSC2
(CompoZr knockout ZFN) and mRNA encoding ZFNs targeting exon 1 of the
PPP1R12C locus (CompoZr Targeted Integration Kit) were from Sigma. Tar-
geting constructs harboring a loxP-flanked PGK promoter-driven neomycin
phosphotransferase cassette surrounded by sequences homologous to the
genomic locus adjacent to the ZFN cut sites were synthesized de novo. Con-
structs were electroporated into SA001 hESCs, which were selected with
0.2 mg/ml G418 (Life Technologies), and clones with site-specific cassette in-
sertions were identified by PCRs from genomic DNA. For more detail, refer to
Supplemental Experimental Procedures.
Neuronal Differentiation
For patterning, NSCs were plated on polyornithin-/laminin-coated dishes at
10,000–15,000 cells/cm2 in basal medium with 100 ng/ml FGF-8 (Pepro-
tech), 200 ng/ml sonic hedgehog (Peprotech), and 100 mM ascorbic acid
2-phosphate (Sigma) and cultured for 1 week. For differentiation, the resul-
tant progenitors were plated at 35,000–50,000 cells/cm2 in basal medium
with 20 ng/ml BDNF, 10 ng/ml glial cell-derived neurotrophic factor
(GDNF; Peprotech), 500 mM dibutyryl cyclic AMP (Sigma), and 100 mM as-
corbic acid 2-phosphate. For more detail, refer to Supplemental Experi-
mental Procedures.
Electrophysiology
Recordings were performed at 22C–24C. Cells were superfused with ACSF
containing (in mM): 123 NaCl, 25 D-Glucose, 10 HEPES, 25 NaHCO3, 5 KCl,
1 NaH2PO4, 2 CaCl2 and 1 MgCl2. Internal solution contained (in mM): 140
KCl, 10 EGTA, 10 HEPES, 2 MgCl2, 2 Na2ATP, 1 Phosphocreatine and 0.3
NaGTP with a pH of 7.28. Gluconate-based solution contained 135 mM
K-gluconate, 20 mM KCl, 10 mM HEPES, 0.1 mM EGTA, 2 mM MgCl2,
2 mM Na2ATP, 1 mM phosphocreatine, and 0.3 mM NaGTP. Borosilicate
glass patch pipettes (2.5–4.0 MU) were used. Cells were patched in the
whole-cell configuration with a stable series resistance of RS < 20 MU.
sEPSCs and mEPSCs were recorded at a membrane potential of 70 mV
in voltage-clamp mode. APs were elicited in current-clamp mode via current
injections of either 1 s or 20 pulses of 10 ms duration. For more detail, refer
to Supplemental Experimental Procedures.
Imaging
Fluorescent images were acquired using a Leica TCS SP5 (Leica Microsys-
tems) inverted microscope, Opera High Content Screening System (Perkin
Elmer) or Operetta High Content Imaging System (PerkinElmer). For data anal-
ysis, refer to Supplemental Experimental Procedures.
Western Blot
Protein samples were resolved on NuPAGE 4%–12% gels and transferred to
nitrocellulose membranes using the iBlot Dry Blotting System (Life Technolo-
gies). Blot scans were acquired using a Li-COR scanner (Odyssey) and
analyzed using the Image Studio Software (Li-COR Biosciences). Antibodies
are listed in Supplemental Experimental Procedures.
Transcriptome Analysis
Real-time qPCR was performed with TaqMan Gene Expression assays (Life
Technologies) using a 96.96 Dynamic Array (Fluidigm). For data analysis, refer
to Supplemental Experimental Procedures.
Mass Spectrometry
Experiments and peak selection were performed as described previously
(Dunkley et al., 2015). For data analysis, refer to Supplemental Experimental
Procedures.Cell Reports 15, 86–95, April 5, 2016 93
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